Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea; Institute of Women's Life Medical Science, Seodaemun-gu, Seoul, Republic of Korea.
Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul, Republic of Korea.
Reprod Toxicol. 2018 Dec;82:88-93. doi: 10.1016/j.reprotox.2018.10.006. Epub 2018 Oct 16.
This retrospective study investigated and compared the incidence of congenital foetal anomalies after letrozole versus clomiphene citrate (CC) administration for infertility treatment. Data from 142 newborns were included: letrozole group, n = 83; CC group, n = 61. Congenital anomalies were found in 7.2% (6/83) patients in the letrozole group and 18.0% (11/61) patients in the CC group, with no significant between-group difference (p = .066). Major congenital anomaly rate was 2.4% (2/83) in the letrozole group and 3.3% (2/61) in the CC group, with no significant between-group difference (p > 0.999). There was no significant difference in major and minor congenital anomalies between the groups after excluding premature infants (birth at a gestational age of <37 weeks), low birth weight, and very low birth weight. The results of this study demonstrate the stability of letrozole compared to that of CC for infertility treatment in pregnant women.
本回顾性研究调查并比较了来曲唑与枸橼酸氯米酚（CC）治疗不孕时导致胎儿先天畸形的发生率。共纳入 142 名新生儿的数据：来曲唑组 83 例，CC 组 61 例。来曲唑组中 7.2%（6/83）患者存在先天畸形，CC 组中 18.0%（11/61）患者存在先天畸形，两组间无显著差异（p=0.066）。来曲唑组中主要先天畸形发生率为 2.4%（2/83），CC 组中为 3.3%（2/61），两组间无显著差异（p＞0.999）。排除早产儿（胎龄＜37 周）、低出生体重儿和极低出生体重儿后，两组间主要和次要先天畸形无显著差异。本研究结果表明，来曲唑在治疗孕妇不孕方面比 CC 更稳定。
